期刊文献+

老年慢性充血性心力衰竭急性加重期β受体阻滞剂剂量调整预后分析 被引量:6

Analysis of prognosis about adjustment of β blocker dosage in elderly patients with chronic congestive heart failure of acute exacerbation stage
下载PDF
导出
摘要 目的:探讨老年慢性充血性心力衰竭急性加重期β受体阻滞剂剂量调整对预后的影响。方法:收集2000年1月~2009年5月住院的各种心血管疾病所致慢性心力衰竭急性加重患者96例,在积极处理诱因,合理氧疗,注意水、电解质、酸碱平衡,合理利用利尿剂、血管扩张剂及洋地黄制剂等治疗的基础上,随机分为原β受体阻滞剂剂量减半组(50例)及全停组(46例),观察患者心衰预后。结果:剂量减半组病情进展15例,好转35例;全停组病情进展25例,病情好转21例,剂量减半组较全停组预后好(P<0.05)。结论:老年患者慢性充血性心力衰竭急性加重期减量使用原β受体阻滞剂与停用相比预后良好,值得临床推广应用。 Objective: To study the effects of adjustment of β blocker dosage during elderly patients with chronic congestive heart failure in acute exacerbation stage on the prognosis. Methods: 96 inpatients due to chronic congestive heart failure in acute exacerbation induced by cardiovascular diseases from January 2000 to May 2009 were randomly divided into two groups, group A (original β blocker dosage was half, 50 cases) and group B (β blocker dosage was out, 46 cases). Each group was actively dealt with predisposing cause, on original base of rational oxygen therapy, keeping water, electrolyte with balance, acid-alkali equilibrium, rational use of diuretic agent, vasodilator agent and digitalis. The prognosis of the two groups was observed. Results: The clinical prognosis of group A was significantly better than that of group B, 15 cases were progressed and 35 cases were improved in group A, 25 cases were progressed and 21 cases were improved in group B. The prognosis of group A was better than that of group B, there was a statistically significant difference between the two groups (P〈0.05). Conclusion: The reduction of using original β blockers in elderly patients with chronic congestive heart failure in acute exacerbation has better prognosis compared with full-stop using, it is worthy of clinical application.
出处 《中国医药导报》 CAS 2010年第9期29-30,共2页 China Medical Herald
关键词 慢性充血性心力衰竭 急性加重期 Β受体阻滞剂 剂量调整 预后 Chronic congestive heart failure Acute exacerbation β blocker Dose adjustment Prognosis
  • 相关文献

参考文献11

  • 1Cibis-Ii Investigators and Committees. The cardiac insufficiency bisoprolol study Ⅱ(CIBIS Ⅱ): a randomized trial [J]. Lancet,1999,353(9146): 9-13.
  • 2MERIT-HF Study Group. Effect of metopmlol CR/XL in chronic heart failure. Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) [J]. Lancet,1999,353(9146):2001-2007.
  • 3Packer M, Fowler M, Rouleau J, et al. The COPERNICUS (calvedilol prospective randomized cumulative survival trial). A multicenter in severe congestive heart failure [J]. Cardiovasc Drugs Ther,1999,13:24.
  • 4Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy [J]. Lancet,1993,347(8885): 1441-1446.
  • 5慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1):7-23. 被引量:2414
  • 6Hunt SA, Abraham MT, Chin MH, et al. ACC/AHA 2005 Guideline in the adult summary article a report of the American college of cardiology/ American heart association task force on practice guidelines [J]. Circulation,2005,112( 12):e154-165.
  • 7Bristow MR, Ginsburg R, Minobe W, et al. Decreased cateeholamine sensitivity and beta-adrenergic-receptor density in failing human hearts [J]. N Engl J Med,1982,307:205-211.
  • 8Poole PA, Swedberg K, Cleand JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with CHF in the carvediIol or metoprolol European trail (COMET): randomized controlled trial [J]. Lancet,2003,357(2267):7-13.
  • 9无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3684
  • 10吴学思.正确掌握β受体阻滞剂在慢性心力衰竭的应用时机[J].中华心血管病杂志,2006,34(9):769-771. 被引量:62

二级参考文献50

  • 1王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:90
  • 2[1]The cardiac insufficiency bisoprolol Study Ⅱ (CIBIS-Ⅱ):a randomised trial.Lancet,1999,353:9-13.
  • 3[2]Effect of metoprolol CR/XL in chronic heart failure.Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).Lancet,1999,353:2001-2007.
  • 4[3]Packer M,Fowler M,Rouleau J,et al.COPERNICUS(carvedilol prospective randomized cumulative survival trial).A multicenter in severe congestive heart failure.Cardiovasc Drugs Ther,1999,13:24.
  • 5[4]Waagstein F,Bristow MR,Swedberg K,et al.Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy.Lancet,1993,342:1441-1446.
  • 6[5]Poole-Wilson PA,Swedberg K,Cleand JG,et al.Comparison of carvedilol and metoprolol on clinical outcomes in patients with CHF in the Carvedilol or Metoprolol European Trail(COMET):randomized controlled trial.Lancet,2003,362:7-13.
  • 7Hunt SA,Baker DW,Chin MH,et al.ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).J Am Coll Cardiol,2001,38:2101-2113.
  • 8Hunt SA,Baker DW,Chin MH,et al.ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).J Am Coll Cardiol,2005,46:1-82.
  • 9Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
  • 10Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.

共引文献6021

同被引文献64

  • 1张莹莹,吕晓红,丁会.老年慢性肺源性心脏病心力衰竭急性加重期患者血清降钙素原与B型利钠肽水平变化[J].中国老年学杂志,2014,34(7):1746-1747. 被引量:30
  • 2夏华玲,李迎春,黄中云.缬沙坦治疗慢性心力衰竭疗效观察[J].临床医学,2006,26(3):36-37. 被引量:13
  • 3无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3684
  • 4Almmth H, Hglund N, Boman K, et al. At orvast at in and persis- tent atrial fibrillation following cardioversion:a randomized place- bo-controlled muhicentre study [ J ]. Eur Heart J, 2009,30 ( 7 ) : 827.
  • 5Johnson NP,Gould KL. Clinical Evaluation of a New Concept: Resting Myocardial Perfusion Heterogeneity Quantified by Mark- ovian Analysis of PET Identifies Coronary Microvascular Dysfunc- tion and Early Atherosclerosis in 1,034 Subjects [ J ]. J Nucl Med, 2005,46 ( 9 ) : 1427.
  • 6Cohn JN, Duprez DA, Grandits GA. Arterial Elasticity as Part of a Comprehensive Assessment of Cardiovascular Risk and Drug Treatment[ J]. Hypertension ,2005,46 ( 1 ) :217.
  • 7Packer M. β-Adrenergic blockade in chronic heart failure:prinbi- pies,progress, and practice [ J ]. Progr Cardiovasc Dis, 1998,41 ( 1 ) :39-52.
  • 8缪国斌,安慧玲,杨君,等.N末端B型利钠肽前体对老年心力衰竭的诊断及预后价值的研究[J/CD].中华临床医师杂志:电子版,2013,12(12):5318-5322.
  • 9van Empel VP, Kaufrnann BA, Bernheim AM, et al. Interaction be- tween pulmonary hypertension and diastolic dysfunction in an elderly heart failure population[ J]. J Card Fail,2014, 20(2) : 98-104.
  • 10Kaszuba E, Wagner B, Odeberg H, et al. Using NT-proBNP to De- tect Chronic Heart Failure in Elderly Patients with Chronic Obstructive Pulmonary Disease[Jl. ISRN Family Med,2013, 2013: 273864.

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部